Photo of Jackie Speier
D United States House · District 14 · California

Rep. Jackie Speier

Compare
Total votes
958
all sessions
Attendance
94%
61 missed
Lower than 94% of chamber peers
With party
98%
of cast votes
Near the chamber average
Bipartisan score
1%
crosses aisle rarely
Near the chamber average
Sponsored
485
bills & resolutions
Near the chamber average
Committees
0
assignments
485 bills and resolutions

Sponsored bills

Total
485
Primary
56
Co-sponsor
429
This page
485
matching current filters
Co-sponsor HR 6117
In committee · United States House · Co-sponsor
PrEP Access and Coverage Act

PrEP Access and Coverage Act This bill requires private health insurance plans to cover prescription drugs that prevent HIV, including related screenings, diagnostic procedures, administrative fees, and clinical follow-ups, without any cost-sharing obligation for the plan holder. Further, insurance plans must not impose any preauthorization requirement for this coverage. These coverage requirements also apply to public health insurance programs, including Medicare, Medicaid, and the Children's Health Insurance Program. Additionally, the bill prohibits denying, limiting, or qualifying coverage or increasing premiums for disability insurance, long-term care insurance, or life insurance policies based on an individual taking medication for HIV prevention. The bill further requires the Department of Health and Human Services to award grants to states, or directly to eligible local organizations, to provide uninsured individuals and underinsured individuals access to prescription drugs and related services that prevent HIV. The Centers for Disease Control and Prevention also must develop a public awareness campaign that focuses efforts in communities with a high need for HIV prevention treatment.

In committee Jan 6, 2022 1 co-sponsor
Co-sponsor HR 6000
In committee · United States House · Co-sponsor
Cures 2.0 Act

Cures 2.0 Act This bill addresses pandemic preparedness and public health issues, caregiver and patient engagement, drug development, insurance coverage, and biomedical research. The Department of Health and Human Services (HHS) must undertake research and other activities concerning COVID-19 and develop a strategy for future pandemics and declared emergencies. Additionally, the bill specifies actions to combat antimicrobial resistance. HHS may award grants for caregiver training. The bill also addresses diversity in clinical trials, collecting patient experience data during clinical trials, and coverage for care related to participation in specified clinical trials. The bill modifies the timeframe and requires additional guidance relating to expedited approval of certain breakthrough drugs, devices, or products. It also establishes two intercenter institutes within the Food and Drug Administration (FDA) focused on particular diseases that meet specified criteria. The bill also addresses (1) coverage in Medicare, Medicaid, and the Children's Health Insurance Program for telehealth, genetic and genomic testing, and other services; (2) electronic prescribing standards for Medicare drug benefits; and (3) access to Medicare and Medicaid claims data by certain registries. Furthermore, the bill prohibits the use of geographic tracking or biometrics in Medicaid electronic visit verification systems. The bill establishes the Advanced Research Projects Agency for Health (ARPA-H) within the National Institutes of Health to accelerate biomedical research and innovation through grants, contracts, cash prizes, and other means. The FDA may work with ARPA-H to expedite the development of medical products through specified activities.

In committee Jan 4, 2022 1 co-sponsor
Co-sponsor HR 3537
Signed into law · United States House · Co-sponsor
Accelerating Access to Critical Therapies for ALS Act

Accelerating Access to Critical Therapies for ALS Act This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions. The Department of Health and Human Services (HHS) shall award grants to eligible entities for scientific research utilizing data from expanded access to investigational ALS treatments for individuals who are not otherwise eligible for clinical trials.  The Food and Drug Administration (FDA) shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other rare neurodegenerative diseases. HHS shall also establish the Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the FDA, and at least one eligible entity (generally, an institution of higher education or a nonprofit organization). The partnership shall support the development and regulatory review of drugs that address ALS and other rare neurodegenerative diseases. The FDA shall publish on its website a five-year action plan for fostering the development of drugs that improve or extend the lives of people living with rare neurodegenerative diseases. The Government Accountability Office must report to Congress about the grants provided under this bill, including an analysis of the impact of such grants on research and development of treatments for ALS.

Signed into law Dec 23, 2021 1 co-sponsor
Co-sponsor HR 5142
Signed into law · United States House · Co-sponsor
To award posthumously a Congressional Gold Medal, in commemoration to the servicemembers who perished in Afghanistan on August 26, 2021, during the evacuation of citizens of the United States and Afghan allies at Hamid Karzai International Airport, and for other purposes.

This bill posthumously provides for the award of a Congressional Gold Medal in commemoration of the 13 service members who died on August 26, 2021, while stationed at Hamid Karzai International Airport in Afghanistan.

Signed into law Dec 16, 2021 1 co-sponsor
Co-sponsor HR 5314
Passed · United States House · Co-sponsor
Protecting Our Democracy Act

Protecting Our Democracy Act This bill addresses issues involving (1) abuses of presidential power; (2) checks and balances, accountability, and transparency; and (3) election integrity and security. Specifically, regarding abuses of presidential power, the bill requires the Department of Justice (DOJ) and the President to submit to Congress specified materials relating to certain pardons, prohibits presidential self-pardons, suspends the statute of limitations for federal offenses committed by a sitting President or Vice President, prohibits the acceptance of foreign or domestic emoluments, and sets forth provisions regarding Office of Government Ethics and Office of Special Counsel jurisdiction and enforcement authority. To address checks and balances, accountability, and transparency, the bill authorizes specified actions to enforce congressional subpoenas, imposes limits on presidential declarations of emergencies, requires DOJ to maintain a log of specified communications between it and the White House, requires cause for removal of inspectors general, increases whistleblower protections, and requires a candidate for President or Vice President to provide copies of tax returns for the 10 most recent taxable years to the Federal Election Commission. To address election integrity and security, the bill requires federal campaign reporting of foreign contacts, makes various changes to requirements concerning foreign donations to political campaigns and candidates and foreign contributions to online electioneering communications, prohibits distribution of materially deceptive audio or visual media prior to an election (i.e., deepfakes), and establishes a program to support states and localities transition to ranked choice voting systems.

Passed Dec 13, 2021 1 co-sponsor
Co-sponsor HR 6207
In committee · United States House · Co-sponsor
Humane Cosmetics Act of 2021

Humane Cosmetics Act of 2021 This bill generally prohibits animal testing in the evaluation of cosmetic products, and it prohibits the sale or transport of cosmetics developed using animal testing, subject to civil penalties. These prohibitions begin one year after enactment. The bill specifies exceptions to these prohibitions, including if such animal testing (1) is conducted outside the United States to comply with a foreign regulatory authority; (2) is pursuant to a specified finding that there are no nonanimal alternatives to test the safety of a potentially dangerous cosmetic product or ingredient; (3) is of a product or ingredient for a drug or device subject to regulation by the Food and Drug Administration (FDA); or (4) is required for a noncosmetic purpose pursuant to a state, federal, or foreign regulatory authority. Further, no animal-testing evidence may be used to establish the safety of a cosmetic product or ingredient that is regulated by the FDA after the effective date of this bill, subject to limited exceptions.

In committee Dec 10, 2021 1 co-sponsor
Co-sponsor HRES 837
Passed · United States House · Co-sponsor
Expressing the sense of the House of Representatives that Beijing should immediately guarantee the safety and freedom of tennis star Peng Shuai.

This resolution expresses the sense of the House of Representatives that the case of Peng Shuai is directly related to broader international concerns around the freedom of speech and safety of athletes participating in the 2022 Olympics in Beijing. The resolution also expresses that the role of the International Olympic Committee (IOC) in legitimizing China's claims about Peng's safety raises questions about the IOC's ability and willingness to protect the rights of athletes participating in the 2022 Olympic and Paralympic games in Beijing. Finally, the resolution expresses that China should (1) provide independent and verifiable proof of Peng's whereabouts and that she is safe, (2) allow Peng to engage directly with the Women's Tennis Association and the United Nations to independently verify her safety and explain her absence from public life since making her allegation, (3) open an independent and transparent investigation into Peng's allegations against former senior Vice Premier Zhang Gaoli, (4) publicly commit to holding sexual violence abusers accountable, (5) cease all censorship of reporting and discussions of Peng's case, and (6) allow Peng to leave China if she so desires and not retaliate against her family members who remain there.

Passed Dec 8, 2021 1 co-sponsor
Co-sponsor HR 1117
In committee · United States House · Co-sponsor
Rosie the Riveter National Historic Site Expansion Act

Rosie the Riveter National Historic Site Expansion Act This bill adds to the Rosie the Riveter/World War II Home Front National Historical Park in California Nystrom Elementary School--The Maritime Building and other areas as the Department of the Interior deems appropriate. Within the boundaries of the park, Interior may acquire lands, improvements, waters, or interests therein by donation, purchase, exchange, or transfer. Any lands, or interests therein, owned by California or any political subdivision of California may be acquired only by donation.

In committee Dec 7, 2021 1 co-sponsor
Co-sponsor HR 6093
In committee · United States House · Co-sponsor
FTC Whistleblower Act of 2021

FTC Whistleblower Act of 2021 This bill provides protections and incentives for whistleblowers who disclose information about, or refuse to participate in, an activity they reasonably believe is a potential violation of any law, rule, or regulation enforced by the Federal Trade Commission. Specifically, it prohibits retaliation against whistleblowers and provides monetary incentives for information that leads to administrative or judicial actions that result in sanctions exceeding $1 million.

In committee Dec 1, 2021 1 co-sponsor
Showing 211 to 220 of 485 bills
Previous 1 … 21 22 23 … 49 Next